Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer

NCT00101907 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00101907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00101907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2004
Completion date
April 30, 2008
Enrollment
41 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, lung cancer, pancreatic cancer